Taiko Pharmaceutical Co's Total Assets for the quarter that ended in Mar. 2024 was 円12,997 Mil.
During the past 12 months, Taiko Pharmaceutical Co's average Total Assets Growth Rate was -31.30% per year.
During the past 3 years, the average Total Assets Growth Rate was -7.10% per year.
During the past 5 years, the average Total Assets Growth Rate was 1.10% per year.
During the past 10 years, the average Total Assets Growth Rate was 6.90% per year.
During the past 13 years, Taiko Pharmaceutical Co's highest 3-Year average Total Assets Growth Rate was 19.30%. The lowest was -7.10%. And the median was 4.15%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Taiko Pharmaceutical Co's Total Assets for the fiscal year that ended in Dec. 2022 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Taiko Pharmaceutical Co (TSE:4574) Total Assets Explanation
Note:
The Net Income data used here is four times the quarterly (Mar. 2024) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Taiko Pharmaceutical Co's Asset Turnover for the quarter that ended in Mar. 2024 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Taiko Pharmaceutical Co Total Assets Related Terms
Thank you for viewing the detailed overview of Taiko Pharmaceutical Co's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Taiko Pharmaceutical Co (TSE:4574) Business Description
Taiko Pharmaceutical Co Ltd operates in three segments, namely Pharmaceutical, Infection Control, and Others. The majority of its revenue comes from Infection Control, which is into manufacturing and sales of sanitation control products, including Cleverin, Cleverin LED, and Cleverin Generator LISPASS. The pharmaceutical segment is into the manufacturing and sales of OTC medicines and designated quasi-drugs. Other business includes manufacturing and sales of wood vinegar-based products.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TSE:4574 has been successfully added to your 